Caxton Corporation Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$249K |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$226K |
| 3 |
Blackstone
BX
|
+$192K |
| 4 |
Lexeo Therapeutics
LXEO
|
+$16.3K |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$13K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$3.28M |
| 2 |
Kyverna Therapeutics
KYTX
|
+$57K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.6% |
| 2 | Financials | 30.5% |
| 3 | Healthcare | 19.57% |
| 4 | Communication Services | 13.32% |
No holdings matched the selected filter criteria.
Similar funds
Caxton Corporation's Q2 2026 Portfolio in Review
As of Q2 2026, Caxton Corporation held 11 positions worth $1.85M, down 54% from $4.02M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Caxton Corporation withdrew a net $2.64M in Q2 2026, closing 1 position and reducing 1 holding. Its most notable exit was SPDR Gold Trust, an estimated $3.28M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 82% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Caxton Corporation opened a new position in Alphabet (Google) Class A worth $247K.
- Caxton Corporation's largest Q2 2026 buy was Alphabet (Google) Class A: 691 shares worth $247K.
- Caxton Corporation added most to Lexeo Therapeutics in Q2 2026, an estimated $16.3K increase.
- Caxton Corporation's biggest Q2 2026 reduction was Kyverna Therapeutics, cutting an estimated $57K.
- Caxton Corporation fully exited SPDR Gold Trust in Q2 2026, selling an estimated $3.28M.
- Caxton Corporation's ten largest holdings make up 100% of its $1.85M portfolio in Q2 2026.
- Caxton Corporation opened 4 new positions and closed 1 in Q2 2026.
- Caxton Corporation's portfolio value fell 54% quarter-over-quarter to $1.85M.
Based on Caxton Corporation's 13F filing for Q2 2026, filed 14 Aug 2026.